Cargando…

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

BACKGROUND: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. OBJECTIVE: The primary objective of the study was to evaluate the appropriate u...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabbara, Wissam K, Ramadan, Wijdan H, Rahbany, Peggy, Al-Natour, Souhaila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410896/
https://www.ncbi.nlm.nih.gov/pubmed/25960658
http://dx.doi.org/10.2147/TCRM.S81280
_version_ 1782368383826657280
author Kabbara, Wissam K
Ramadan, Wijdan H
Rahbany, Peggy
Al-Natour, Souhaila
author_facet Kabbara, Wissam K
Ramadan, Wijdan H
Rahbany, Peggy
Al-Natour, Souhaila
author_sort Kabbara, Wissam K
collection PubMed
description BACKGROUND: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. OBJECTIVE: The primary objective of the study was to evaluate the appropriate use of commonly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in renal impairment, and duration of treatment. The secondary objective was to investigate the dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic and nondiabetic patients. METHODS: A prospective observational study at a teaching hospital in Lebanon was conducted over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones (levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited from internal medicine floors and intensive care units. RESULTS: The final percentage for the appropriate indication, dose, and duration of fluoroquinolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients did not receive the appropriate dose adjustment according to their level of renal impairment. In addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin (39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%). CONCLUSION: The major clinical interventions for the future will adjust the dose and duration of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was less common than hyperglycemia.
format Online
Article
Text
id pubmed-4410896
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44108962015-05-08 Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia Kabbara, Wissam K Ramadan, Wijdan H Rahbany, Peggy Al-Natour, Souhaila Ther Clin Risk Manag Original Research BACKGROUND: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. OBJECTIVE: The primary objective of the study was to evaluate the appropriate use of commonly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in renal impairment, and duration of treatment. The secondary objective was to investigate the dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic and nondiabetic patients. METHODS: A prospective observational study at a teaching hospital in Lebanon was conducted over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones (levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited from internal medicine floors and intensive care units. RESULTS: The final percentage for the appropriate indication, dose, and duration of fluoroquinolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients did not receive the appropriate dose adjustment according to their level of renal impairment. In addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin (39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%). CONCLUSION: The major clinical interventions for the future will adjust the dose and duration of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was less common than hyperglycemia. Dove Medical Press 2015-04-22 /pmc/articles/PMC4410896/ /pubmed/25960658 http://dx.doi.org/10.2147/TCRM.S81280 Text en © 2015 Kabbara et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kabbara, Wissam K
Ramadan, Wijdan H
Rahbany, Peggy
Al-Natour, Souhaila
Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
title Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
title_full Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
title_fullStr Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
title_full_unstemmed Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
title_short Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
title_sort evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410896/
https://www.ncbi.nlm.nih.gov/pubmed/25960658
http://dx.doi.org/10.2147/TCRM.S81280
work_keys_str_mv AT kabbarawissamk evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia
AT ramadanwijdanh evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia
AT rahbanypeggy evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia
AT alnatoursouhaila evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia